ReviewClinical microbiology reviews2011
Challenges of antibacterial discovery.
Review in Clinical microbiology reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 559 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
559 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current State of Knowledge Regarding WHO High Priority Pathogens-Resistance Mechanisms and Proposed Solutions through Candidates Such as Essential Oils: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Exosomes delivering a high-throughput-screened RNA polymerase inhibitor for highly effective therapy of multidrug-resistant bacterial infected pneumonia.Bioactive materials · 2026Article
- Serial-Passage Assessment Shows No Confirmed Resistance Development to Norway Spruce (Picea Abies) Resin in Bacterial Species Relevant to Wound Infection.MicrobiologyOpen · 2026Article
- Artificial Intelligence-Driven Antimicrobial Peptide Discovery: Prediction, Generation, Mining and Optimization.Probiotics and antimicrobial proteins · 2026Review
- Random Forest Modeling to Predict Small Molecule Accumulation in Gram-Negative Bacteria.ACS infectious diseases · 2026Article
- Discovery and Optimization of Novel Nonhydroxamate LpxC Inhibitors for the Treatment of Multidrug-Resistant Gram-Negative Infections.Journal of medicinal chemistry · 2026Article
- Structural insights into multitargetingMicrobiology spectrum · 2026Article
- Bioactive Coatings with Antimicrobial Activity fromMolecules (Basel, Switzerland) · 2026Review
- Control Targets in Plant-Pathogenic Bacteria: From Growth-Essential Processes to Anti-Virulence Strategies and Candidate Targets inPlants (Basel, Switzerland) · 2026Review
- Article
- Antimicrobial, antibiofilm, antioxidant activities and molecular docking of Schiff base and its complexes of Cu(II), Co(II), Ni(II), Mn(II) and UOScientific reports · 2026Article
- Photochemical modification of two fluorene-based molecules with DNA intercalating and anti-methicillin resistant Staphylococcus aureus activity.The Journal of biological chemistry · 2026Article
- Exploring FabH inhibitors for antimicrobial therapy: medicinal chemistry, synthetic approaches, and SAR evaluation.Molecular diversity · 2026Review
- Secretin-interacting plug proteins prevent antibiotic influx during type IV pilus assembly in Pseudomonas aeruginosa.Nature communications · 2026Article
- The genetic landscape of antibiotic sensitivity inScience advances · 2026Article
- CLABP: a contrastive learning framework integrating protein language models and structural information for antibacterial peptide prediction.Briefings in bioinformatics · 2026Article
- Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.EMBO molecular medicine · 2026Review
- NV716 acts as an envelope-active adjuvant that enhances antibiotic accumulation in Pseudomonas aeruginosa.npj antimicrobials and resistance · 2026Article
- Baloxavir Exhibits Antibacterial Activity AgainstInternational journal of molecular sciences · 2026Article
- Article
499 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of novel small-molecule antibacterial drugs has been stalled for many years. The purpose of this review is to underscore and illustrate those scientific problems unique to the discovery and optimization of novel antibacterial agents that have adversely affected the output of the effort. The major challenges fall into two areas: (i) proper target selection, particularly the necessity of pursuing molecular targets that are not prone to rapid resistance development, and (ii) improvement of chemical libraries to overcome limitations of diversity, especially that which is necessary to overcome barriers to bacterial entry and proclivity to be effluxed, especially in Gram-negative organisms. Failure to address these problems has led to a great deal of misdirected effort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.